KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Takeda Pharmaceutical (TAK) Net Income towards Common Stockholders (2025)

Takeda Pharmaceutical has reported Net Income towards Common Stockholders over the past 1 years, most recently at $913.6 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders changed N/A year-over-year to $913.6 million; the TTM value through Mar 2026 reached $913.6 million, changed N/A, while the annual FY2026 figure was $1.3 billion, 79.8% up from the prior year.
  • Net Income towards Common Stockholders was $913.6 million for Q4 2025 at Takeda Pharmaceutical.
  • Across five years, Net Income towards Common Stockholders topped out at $913.6 million in Q4 2025 and bottomed at $913.6 million in Q4 2025.